Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie and Calico announce a novel R&D collaboration to discover, develop and commercialize new therapies for age-related diseases including neurodegeneration…
Covers the 2018 $1B extension of the Calico-AbbVie deal, noting continued investment despite limited public clinical data after four years and questioning the…
Documents AbbVie's exit from the Calico partnership and characterizes the longevity bet as having delivered limited clinical success despite over $1B in…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AbbVie and Alphabet-backed Calico Life Sciences each committed up to $250M upfront with the option for an additional $500M each (total potential $1.5B), pooling resources for aging-related drug discovery centered in the Bay Area. AbbVie ultimately ended the 11-year collaboration in 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Calico LLC (this deal) | 2014 | $1.5B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2014 deals · AbbVie Inc. deals · Neurology deals